Browsing Tag
Huntington’s disease
7 posts
uniQure (NASDAQ: QURE) sinks after FDA mandates Phase III trial for Huntington’s therapy AMT-130
uniQure (QURE) plunges after FDA demands a Phase III trial for AMT-130 in Huntington’s disease. What this means for valuation and next steps.
Ipsen secures global licensing option for Origami’s selective protein degrader platform
Ipsen has signed a global option deal with Origami Therapeutics for a rare CNS protein degrader. Find out what this signals for neuro drug strategy.
uniQure moves closer to FDA approval as AMT-130 gene therapy shows progress for Huntington’s disease
Find out how uniQure’s AMT-130 regulatory path for Huntington’s disease is evolving after the FDA’s latest feedback on its data sufficiency.
Can pridopidine finally change the trajectory of Huntington’s disease progression?
Can pridopidine change the course of Huntington’s disease? Explore key data from the Nature Medicine study and what’s next for Prilenia’s regulatory path.
Breakthrough data from Vatiquinone trials propels PTC Therapeutics stock to 52-week high
PTC Therapeutics Inc. (NASDAQ: PTCT) is experiencing significant momentum within the biotechnology sector following a surge in its…
Huntington’s Disease : Understanding Its Impacts and Treatments
Huntington’s disease is a severe neurodegenerative disorder, characterized by its autosomal dominant inheritance pattern. This condition leads to…
Teva Pharmaceutical gets FDA approval for AUSTEDO XR for TD and HD
Teva Pharmaceutical Industries said that its US affiliate Teva Pharmaceuticals has secured approval for AUSTEDO XR (deutetrabenazine) extended-release…